Transient receptor potential canonical (TRPC) channels are known to play a key role in regulating nervous system excitability and they have been previously implicated in seizure development.
Antimicrobial peptides, existing in animals and plants, are the first line of defense of the organisms against bacteria. Thymol and carvacrol are two monoterpenoids with known antibacterial activity exerted through bacterial cell membrane structural disruption, which contributes to a lower risk of developing resistance compared to antibiotics acting against specific targets on cells.
Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent herpes simplex virus 1 (HSV-1) keratitis.
Following the World Health Organization’s escalation of mpox to a public health emergency of international concern on Aug. 14 and the emergence of what appears to be a more severe strain of the orthopoxvirus, the spotlight has focused on a handful of companies working on vaccines and antivirals. Shares of Geovax Labs Inc., Emergent Biosolutions Inc. and Tonix Pharmaceuticals Inc. were all trading up Aug. 19.
Shares of Chinese and South Korean med-tech companies continued to rise after the World Health Organization declared mpox a public health emergency of international concern Aug. 14 after recent outbreaks.
The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.
Researchers from Thomas Jefferson University and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) have published findings from preclinical studies of LASSARAB, a new rabies-based Lassa virus (LASV) vaccine candidate.
About two months after Astrazeneca plc said its application for sipavibart (AZD-3152) had been accepted by the EMA for pre-exposure prophylaxis (PrEP) against COVID-19 in immunocompromised people, Invivyd Inc. unveiled positive 180-day exploratory efficacy data from the company’s ongoing Canopy phase III trial with Pemgarda (pemivibart) in the same indication – and made known less happy news from regulators on the other side of the pond.
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
RSS
